- The project will evaluate the real-world impact
of Brainomix's e-Lung imaging software to improve the
identification and access to treatment for people with progressive
pulmonary fibrosis in the US.
OXFORD, England and
CHICAGO, July 18, 2024 /PRNewswire/ -- Brainomix, a
pioneer in artificial intelligence (AI) imaging solutions, has
announced it has entered into a partnership with German
pharmaceutical company Boehringer Ingelheim for
a collaborative programme of activity to improve the care
of patients with fibrosing lung disease in the US.
This landmark project will focus on the opportunity for AI
imaging analysis using Brainomix 360 e-Lung on routine CT
scans to accelerate the diagnosis and improve access to treatment
for people living with fibrosing lung disease.
Pulmonary fibrosis is a chronic lung condition that is
progressive and life-limiting. Untreated, patients can have a
lifespan as short as 5 years from diagnosis, and yet despite this,
often wait up to 2 years for diagnosis. The key to the best
survival for patients with fibrosing lung disease is the earliest
initiation of treatment, but identifying patients eligible for
treatment based on imaging can be challenging, even for
experts.
Through this partnership, Brainomix will deploy its FDA-cleared
e-Lung software to leading US pulmonology centers and their
networks of referring sites. The data generated will validate the
value of e-Lung, highlighting the potential of digital technology
to optimize pathways of care and improve outcomes for people with
fibrosing lung disease, a vision shared between Brainomix and
Boehringer Ingelheim.
Dr Michalis Papadakis, CEO and
Co-Founder of Brainomix said: "There is an urgent need to
improve the identification of people with fibrosing lung disease.
This will enable earlier access to specialist care and the
opportunity for faster initiation of treatment, which can slow the
worsening of the disease. The patient pathway for people with
fibrosing lung disease is currently fragmented and, it can take
many years for a patient to be diagnosed.
"This partnership enables us to leverage our established
experience and expertise connecting stroke networks to develop a
similar network model of care for patients with fibrosing lung
disease, generating real-world evidence that will drive the
opportunities we have with e-Lung to help improve outcomes for
patients and their families."
Ioannis Sapountzis, Head of
Global Therapeutic Areas at Boehringer Ingelheim said: "At
Boehringer Ingelheim, we know how critical early and confident
detection of progression is for people living with fibrosing lung
disease. We believe that Brainomix 360 e-Lung has the potential to
revolutionize the diagnostic landscape and thereby enable earlier
treatment decisions at a pivotal stage of the patient's journey.
This can ultimately improve patient outcomes and quality of life of
those affected."
Brainomix 360 e-Lung received FDA clearance in May 2024, the same month the company announced a
series of new studies highlighting the prognostic value of its
lung imaging biomarkers in patients with fibrotic lung disease. The
studies, presented at the American Thoracic Society (ATS)
Conference in San Diego, reflect
the company's expanding Life Sciences partnerships and academic
collaborations with luminary research centers in the lung
space.
About Brainomix
Brainomix specializes in the creation of AI-powered software
solutions to enable precision medicine for better treatment
decisions in stroke and lung fibrosis. With origins as a spin-out
from the University of Oxford, Brainomix is an expanding
commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries.
A private company, backed by leading healthtech investors,
Brainomix has innovated award-winning imaging biomarkers and
software solutions that have been clinically adopted in hundreds of
hospitals worldwide. Its first product, the Brainomix 360 stroke
platform, provides clinicians with the most comprehensive stroke
imaging solution, driving increased treatment rates and improving
functional independence for patients.
To learn more about Brainomix and its technology
visit www.brainomix.com, and follow us
on Twitter, LinkedIn and Facebook.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in
both human and animal health. As one of the industry's top
investors in Research and Development, the company focuses on
developing innovative therapies in areas of high unmet medical
need. Independent since its foundation in 1885, Boehringer takes a
long-term perspective, embedding sustainability along the entire
value chain. More than 53,500 employees serve over 130 markets to
build a healthier, more sustainable, and equitable tomorrow. Learn
more at www.boehringer-ingelheim.com.
Contacts
Jeff Wyrtzen,
Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730
Media enquiries
Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585
Photo -
https://mma.prnewswire.com/media/2463630/Brainomix2024.jpg
Logo -
https://mma.prnewswire.com/media/1989193/Brainomix_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/brainomix-and-boehringer-ingelheim-launch-strategic-partnership-in-fibrosing-lung-disease-302200448.html